Study S002136

A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALN-2232 as Monotherapy and Co-initiated With Tirzepatide in Adult Participants With Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07463846
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1; PHASE2
Masking: TRIPLE
Status: RECRUITING
Enrollment: 156
Start: 2026-03-02
Primary completion: 2027-04-28
Lead sponsor: Alnylam Pharmaceuticals
Conditions: Obesity
Interventions: DRUG:ALN-2232; DRUG:Placebo; DRUG:Tirzepatide
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Part A: Frequency of Adverse Events (AEs) [Up to 12 months]
Part B: Percent Change from Baseline in Body Weight [Baseline up to Month 6]
Part C: Percent Change from Baseline in Body Weight [Baseline up to Month 6]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.